Phase 2 N=157 Assessing PA-824 for Tuberculosis (the APT Trial)
Pulmonary Tuberculosis
Primary: Time to Sputum Culture Conversion on Liquid Medium — 42; 28; 56; 42 days — p=0.10
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 A New Treatment for Mechanical Nasal Obstruction
Nasal Obstruction
Primary: Change in Peak Nasal Inspiratory Flow (PNIF) — 28; 24; 13; 27 liters per minute
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
N/A N=93 Cala ONE Device for Essential Tremor
Essential Tremor
Primary: Change in TETRAS Spiral Rating After Stimulation — 2.95; 2.63; 2.41; 2.23 score on a scale
Phase 2 N=17 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
Chronic Obstructive Pulmonary Disease · Emphysema
Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change
Phase 3 N=22 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
Dupuytren's Disease
Primary: Health-related Quality of Life (HRQL) Using the Michigan Hand Outcomes Questionnaire (MHQ) — 78.1; 68.3 units on a scale — p=0.05
Phase 1 N=20 A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule
Healthy
Primary: Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 150.65; 148.34 hours…
Phase 1 N=16 A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Caffeine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity, Caffeine) — 84569.29; 94764.64 hours…
N/A N=379 Augmenting Cognitive Training In Older Adults
Aging
Primary: Improvement in Cognitive Ability. — 4.7; 4.5 units on a scale — p=<0.05
Phase 1 N=80 Feasibility of VOICES Elder Abuse Intervention in Primary Care Setting (VOICES-PC Feasibility)
Elder Abuse
Primary: Participation — 80 Participants
Phase 2 N=22 Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Primary: Maximum Tolerated Dose (MTD) of Bosutinib All Phase I Participants — 400 Milligrams
Phase 3 N=424 MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
Lateral Canthal Lines · Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Phase 3 N=202 Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia
Hypercholesterolemia
Primary: The Percentage Change From Baseline in LDL-C Level at Week 12. — -42.89; -37.43 Percent change from baseline
Phase 4 N=961 A Sourcing Study to Collect Human Blood Samples From Healthy Adults
Meningitis, Meningococcal
Primary: Number of Human Blood Samples Collected for Conversion Into Serum at Day -83 — 5578; 1936 Blood samples
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants